Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Promotion · Healthcare Marketing Communication

Healthcare and Medical Marketing Communication: Rules, Risks, and Good Practice

U.S. spending on direct-to-consumer prescription drug advertising rose from about $1.3 billion in 1998 to roughly $4.2 billion by 2005. This growth prompted the FDA’s own enforcement framework and published Good Publication Practice recommendations for the publication of company-sponsored medical research.

Pubrica AcademyWritten by a healthcare communications specialist Reviewed bya regulatory affairs reviewer Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources10 peer-reviewed

Healthcare and medical marketing communication covers how pharmaceutical, device, and healthcare-service information reaches both clinicians and the public, including direct-to-consumer drug advertising, sponsored or company-funded medical research communication, and promotional materials for healthcare products and services. The field sits under specific, documented regulatory and ethical frameworks precisely because the same claim, about a drug's efficacy, a device's safety profile, or a study's findings, can be stated in ways that are technically accurate but materially misleading, and both the FDA and the standards bodies governing sponsored research communication have established detailed rules to address that gap.

Learning objectives

  • The measured growth in direct-to-consumer drug advertising expenditure that prompted regulatory scrutiny
  • The requirements of the FDA regulatory framework for prescription drug advertising
  • The recommendations of Good Publication Practice (GPP 2022) for publishing company-sponsored biomedical research

Common misconceptions

  • “Pharmaceutical marketing and the communication of sponsored clinical research are governed by essentially the same loosely defined norms.” Direct-to-consumer advertising is governed specifically by FDA regulation under 21 CFR 202.1 and enforced by the agency's Office of Prescription Drug Promotion, while the publication of company-sponsored medical research results is addressed by separate professional guidance: GPP 2022 provides recommendations for the publication of company-sponsored biomedical research, with its own recommendations on authorship, transparency and timing.

Growth of direct-to-consumer drug advertising expenditure

Julie Donohue, Marisa Cevasco, and Meredith Rosenthal's 2007 analysis in the New England Journal of Medicine documented the scale of this growth: spending on direct-to-consumer prescription drug advertising in the United States rose from approximately $1.3 billion in 1998 to roughly $4.2 billion by 2005, a more than threefold increase over seven years, driven substantially by television advertising1. The same analysis found that this growth outpaced growth in pharmaceutical promotional spending directed at physicians over the same period, a shift in the industry's overall promotional balance toward communicating directly with the end patient rather than exclusively through the prescribing clinician1. Donohue and colleagues specifically link this growth to the FDA's 1997 clarification of broadcast advertising rules, which made television-format direct-to-consumer advertising substantially more practical for manufacturers than it had been under the agency's earlier, more restrictive interpretation1.

Requirements of FDA regulation for drug advertising

FDA's prescription drug advertising regulation, codified at 21 CFR 202.1, requires that any advertisement present a "fair balance" between a drug's effectiveness claims and its risk information, and prohibits advertising that is false or misleading in any particular, including through the omission of material facts2. The agency's Office of Prescription Drug Promotion is specifically responsible for reviewing promotional materials and enforcing these requirements, including issuing untitled letters for violations that fall short of requiring immediate corrective action and warning letters for more serious violations requiring prompt correction3. This regulatory structure addresses a specific gap that technically accurate advertising can exploit: a claim can state a true statistic about a drug's benefit while omitting comparably material risk information, which is precisely the “fair balance” requirement's intended target, rather than simply prohibiting false statements outright2.

The standard for communicating sponsored research

Separately from advertising regulation, the publication of company-sponsored medical research, through publications, conference presentations, and related materials, is addressed by Good Publication Practice. GPP 2022 provides recommendations for the publication of company-sponsored biomedical research; it updated GPP3, published by William Battisti, Elizabeth Wager, and colleagues in the Annals of Internal Medicine in 2015 as an update to earlier GPP standards4. GPP3 set out specific requirements distinct from advertising rules: authorship on any sponsored-research publication must still meet ICMJE's criteria regardless of funding source, the sponsor's role in the research and in preparing the communication must be disclosed explicitly, data should be made available for independent verification where feasible, and results should be communicated regardless of outcome, specifically prohibiting selective communication of favorable findings only4. The World Health Organization's long-standing ethical criteria for medicinal drug promotion add a complementary international framework, recommending that promotional claims be consistent with nationally approved product information and that comparative claims be factual, fair, and capable of substantiation, principles that apply across both advertising and sponsored-research communication contexts5.

Industry codes governing interactions with clinicians

A third layer, distinct from both consumer advertising and sponsored-research communication, governs how pharmaceutical and device companies communicate with healthcare professionals directly, including through sales representatives, sponsored continuing-education events, and promotional materials provided to clinicians. The Pharmaceutical Research and Manufacturers of America's Code on Interactions with Healthcare Professionals sets out voluntary industry standards specifically for this channel, including that promotional communications to healthcare professionals be accurate, balanced, and consistent with the product's approved labeling, and that educational or scientific exchange be clearly distinguished from promotional messaging rather than blended into it6. This layer is important because the fair-balance requirement that governs direct-to-consumer advertising under FDA regulation and the disclosure recommendations GPP 2022 sets out for publishing company-sponsored research do not, by themselves, cover every interaction a company has with a prescriber; promotional speaker programs, sponsored medical conference symposia, and representative-delivered materials are a distinct category with their own code-based expectations layered on top of, not replacing, the baseline FDA requirement that any claim made to a clinician also be consistent with approved labeling and substantiated by evidence3. For organizations producing healthcare marketing communication across all three channels, consumer advertising, sponsored-research publication, and clinician-directed promotion, keeping the applicable framework for each channel explicit, rather than assuming a single compliance review covers all three, is the practical safeguard against compliance gaps at the boundaries between them.

Application of these rules to digital and social media promotion

None of these frameworks, FDA's fair-balance requirement, GPP3's research-communication standard, or PhRMA's clinician-interaction code, were originally written with social media or short-form digital content specifically in mind, but each has been extended in practice to cover it rather than treated as inapplicable simply because the format is new. FDA's Office of Prescription Drug Promotion has specifically addressed character-limited and visually constrained digital formats, clarifying that the fair-balance requirement for presenting risk information alongside benefit claims applies regardless of a platform's space constraints, which in practice has moved much risk-information disclosure in short-form social posts toward linked or referenced full prescribing information rather than attempting to compress it into the post itself3. For sponsored-research communication specifically, GPP 2022's disclosure and authorship recommendations apply equally to a conference-presentation summary posted on social media by a sponsor or a medical-writing agency as to the full publication itself, meaning a social post highlighting a trial's results should still reflect the same balanced, complete presentation of outcomes expected of the primary publication, not a selectively favorable excerpt from it4. The practical implication for any organization producing healthcare marketing content digitally is that format constraints change the presentation, not the underlying compliance obligation, which remains identical to its print or in-person equivalent under whichever of the three frameworks applies to that specific piece of content.

International variation in these rules

The advertising and promotion frameworks described throughout this topic, FDA regulation and the PhRMA code, are specifically American in their direct legal or industry-association authority, and organizations communicating healthcare and medical information internationally should recognize that direct-to-consumer advertising of prescription drugs is treated very differently outside the United States, where most countries, including across the European Union, prohibit it for prescription-only medicines entirely, permitting only disease-awareness campaigns that stop short of naming or promoting a specific branded product2. The World Health Organization's ethical criteria for medicinal drug promotion function as the nearest equivalent to an international baseline because they were designed to be adopted or adapted by national regulators across very different legal systems, but their enforcement in any given country depends entirely on that country's own regulatory body choosing to adopt and apply them, which means the WHO criteria describe a recommended standard rather than a directly enforceable one on their own5. For any organization producing healthcare marketing communication across multiple countries, the practical implication is that GPP 2022's recommendations for publishing company-sponsored research are reasonably transferable internationally, since they are professional publication guidance rather than a national regulation, while consumer-facing advertising compliance must be checked separately against each specific country's own, often considerably more restrictive, regulatory framework. This distinction should be stated explicitly in any internal compliance guidance a multinational healthcare organization maintains, since a single global template built around the U.S. direct-to-consumer advertising rules will, if applied unchanged elsewhere, both miss stricter local prohibitions and fail to reflect the specific disease-awareness-only exception many other jurisdictions permit in its place.

Key points

Key points

Healthcare marketing communication and the publication of company-sponsored research are addressed by distinct frameworks, both of which address the gap between technical accuracy and genuine fairness: the FDA’s fair-balance requirement for advertising, and the GPP 2022 recommendations for disclosure, authorship and complete reporting of company-sponsored biomedical research. Conflating the two leaves substantive compliance gaps.

Practical application

Practical application

  1. Promotional materials should be checked against the fair-balance requirement specifically, not only for factual accuracy. It should be confirmed that risk information receives prominence and clarity comparable to effectiveness claims, because omission of material risk is itself a regulatory violation.
  2. The GPP 2022 authorship and disclosure recommendations should be applied to the publication of company-sponsored research. Authorship should meet ICMJE criteria regardless of funding source, and the specific role of the sponsor should be disclosed explicitly.
  3. A commitment to communicate sponsored research results regardless of outcome should be made before the study begins. Good Publication Practice recommends against selective reporting of favorable results only; a pre-specified communication plan covering all outcomes should therefore be established.

Frequently asked questions

No. Advertising is governed by FDA regulation (21 CFR 202.1) enforced by the Office of Prescription Drug Promotion, whereas GPP 2022 provides recommendations for the publication of company-sponsored biomedical research; the two have distinct requirements.

It requires that an advertisement present risk information with prominence and clarity comparable to its effectiveness claims; omitting material risk information while presenting a true effectiveness statistic can still violate this requirement even without an outright false statement.

No. GPP 2022 provides recommendations for the publication of company-sponsored biomedical research, including conference presentations and related materials, not only peer-reviewed publications.

Good Publication Practice recommends against this, calling for results to be communicated regardless of outcome; selective communication of favorable findings only is directly contrary to the guidance's stated purpose.

Donohue and colleagues link the rise specifically to the FDA's 1997 clarification of broadcast advertising rules, which made television-format advertising substantially more practical for manufacturers than under the agency's prior, more restrictive interpretation.

References

  1. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7):673-681. read 10 October 2026. View on NEJM
  2. U.S. Food and Drug Administration. 21 CFR 202.1 - Prescription Drug Advertisements. read 10 October 2026. View on eCFR
  3. U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP). read 10 October 2026. View on FDA
  4. Battisti WP, Wager E, Baltzer L, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163(6):461-464. read 10 October 2026. View on Annals of Internal Medicine
  5. Pharmaceutical Research and Manufacturers of America. PhRMA Code on Interactions with Healthcare Professionals. read 10 October 2026. View on PhRMA
  6. U.S. Food and Drug Administration. 21 CFR 202.1 - Prescription Drug Advertisements. read 10 October 2026. View on eCFR
  7. Battisti WP, Wager E, Baltzer L, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163(6):461-464. read 10 October 2026. View on Annals of Internal Medicine
  8. International Committee of Medical Journal Editors. Defining the Role of Authors and Contributors. read 10 October 2026. View on ICMJE
  9. World Health Organization. Ethical Criteria for Medicinal Drug Promotion. read 10 October 2026. View on WHO
  10. U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP). read 10 October 2026. View on FDA

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Healthcare and Medical Marketing Communication: Rules, Risks, and Good Practice. Pubrica. https://pubrica.com/academy/healthcare-and-medical-marketing-communication/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Sponsored Research Communication Checklist

This checklist should be used before company-sponsored medical research is communicated in any format.

[ ] Confirmed authorship meets ICMJE criteria regardless of funding source
[ ] Disclosed the sponsor's specific role in research and in preparing the communication
[ ] Committed to communicating results regardless of outcome (pre-specified before the study)
[ ] Checked promotional claims (if any) against fair-balance requirements for risk/benefit presentation
[ ] Verified comparative claims are factual, fair, and substantiated per WHO's ethical criteria
[ ] Made data available for independent verification where feasible

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s medical communications team prepares sponsored-research publications in line with GPP 2022 and the ICMJE Recommendations, and promotional materials in line with FDA fair-balance requirements, rather than treating advertising and research-communication compliance as interchangeable.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Aligning sponsored-research communication plans with GPP 2022 as well as advertising rules

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.